Clinical Trial Update: Sirolimus Prophylaxis for aGVHD in TME SCID [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating sirolimus prophylaxis for acute graft-versus-host disease in Severe Combined Immunodeficiency with transplacental maternal engraftmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Combined Immunodeficiency

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: University of California, San Francisco | Conditions: Severe Combined Immunodeficiency, Transplacental Maternal Engraftment | Phase 2 | Status: WITHDRAWN